DeutschNewstral
Article
Forbes on 2018-09-27 13:00
Alnylam Touts Positive Data On Second Drug, Plans FDA Meeting
Related news
FDA gives early OK to Alnylam rare disease drugbizjournals.com- Alnylam releases promising data on rare disease drugbizjournals.com
- MAlnylam rare drug gets FDA approval, to cost $345,000 on averagemarketwatch.com
- MAlnylam shares jump on FDA approvalmarketwatch.com
- BRebranded FoundersForge touts positive momentum during summit meetingbjournal.com
FDA plans meeting to discuss safety data on breast implantslasvegassun.com- Alnylam plans Cambridge expansion after $2B investmentbizjournals.com
- Longtime Alnylam exec Barry Greene leaving biotechbizjournals.com
Fauci touts 'significant, positive' data from trial of possible Covid-19 treatment remdesivirCNN- MChakwera touts Brics meetingmwnation.com
- With positive trial data in hand, Durham drugmaker looks ahead to FDA approvalbizjournals.com
- Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA AuthorizationForbes
- BModerna Announces Positive Data on Vaccine in Young Children, Will Ask FDA for Authorization3 min readbarrons.com
- MAlnylam shares drop 1.8% on new FDA approval strategy for rare disease drugmarketwatch.com
- Alnylam plans to divvy new hires between Cambridge and Philadelphiabizjournals.com